Stock Performance and Market Context
On 4 December 2025, Venus Remedies opened with a gap up of 4.94%, signalling robust buying interest at the start of the trading session. The stock touched an intraday high of Rs.808.5, setting a fresh 52-week and all-time peak. Despite this, the share price experienced some volatility, dipping to an intraday low of Rs.731.95, representing a 5% decline from the opening level. By the close, the stock recorded a slight day change of -0.32%, underperforming its sector by 4.86% on the day.
Venus Remedies is currently trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates a sustained upward trend over multiple time horizons, reinforcing the stock’s positive momentum.
In comparison, the broader market benchmark, the Sensex, experienced a recovery after a negative start, closing at 85,284.08 points, up 0.21%. The Sensex remains 1.03% below its own 52-week high of 86,159.02, with mid-cap stocks leading gains at 0.25%. Venus Remedies’ performance notably outpaces the Sensex’s 5.35% return over the past year, with the stock delivering a substantial 134.93% gain during the same period.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Highlights Driving the Rally
Venus Remedies’ recent financial disclosures reveal a strong growth trajectory. The company reported a net profit of Rs.29.73 crores over the latest six-month period, reflecting a growth of 528.54% compared to previous periods. Profit before tax excluding other income for the quarter stood at Rs.24.78 crores, showing an exceptional increase of 2073.68%. These figures highlight the company’s expanding profitability and operational efficiency.
The return on capital employed (ROCE) for the half-year period reached 13.99%, the highest recorded in recent times, while the return on equity (ROE) stands at 10.5%. These metrics indicate effective utilisation of capital and shareholder funds, contributing to the stock’s upward momentum.
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which suggests a conservative capital structure and limited reliance on borrowed funds. This financial prudence may have contributed to investor confidence and the stock’s sustained rally.
The company has declared positive results for four consecutive quarters, reinforcing a pattern of consistent performance. Over the past year, profits have risen by 183%, complementing the stock’s price appreciation. The price-to-book value ratio of 1.7 positions the stock at a fair valuation relative to its peers and historical averages.
Curious about Venus Remedies from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Long-Term Performance and Market Position
Venus Remedies has demonstrated market-beating performance not only over the past year but also in the medium term. The stock has outperformed the BSE500 index over the last three years, one year, and three months, underscoring its resilience and growth potential within the Pharmaceuticals & Biotechnology sector.
The 52-week low for the stock was Rs.272.2, indicating a substantial appreciation in value over the year. This wide price range reflects the company’s transformation and the market’s evolving perception of its prospects.
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence may reflect a cautious stance or differing assessments of the company’s valuation and business model among institutional investors.
Trading Dynamics and Volatility
Following three consecutive days of gains, Venus Remedies experienced a slight pullback today, illustrating typical price fluctuations after a strong rally. The stock’s ability to maintain levels above all major moving averages suggests underlying strength despite short-term volatility.
The day’s trading range, from Rs.731.95 to Rs.808.5, highlights active market participation and investor engagement. The opening gap up of nearly 5% signals positive sentiment at the start of the session, while the intraday low indicates profit-taking or market adjustments.
Overall, the stock’s trajectory towards a new 52-week high is a testament to its robust fundamentals and the sector’s favourable environment.
Sector and Industry Context
Venus Remedies operates within the Pharmaceuticals & Biotechnology sector, which continues to attract attention due to ongoing innovation and demand for healthcare products. The sector’s performance today was mixed, with Venus Remedies underperforming by 4.86% relative to its peers. However, the stock’s long-term gains and recent milestone highlight its distinctive position within the industry.
The broader market’s positive trend, with the Sensex trading above its 50-day moving average and mid-cap stocks leading gains, provides a supportive backdrop for Venus Remedies’ continued momentum.
Summary
Venus Remedies’ achievement of a new 52-week high at Rs.808.5 marks a significant milestone in its market journey. Supported by strong financial results, favourable valuation metrics, and technical strength, the stock has demonstrated notable resilience and growth over the past year. While short-term fluctuations are evident, the overall trend reflects a company that has gained considerable ground within the Pharmaceuticals & Biotechnology sector.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
